First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants

NCT07412288 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Participants

Interventions

DRUG: KT-579
DRUG: Placebo

Sponsor

Kymera Therapeutics, Inc.